Accessibility Menu
BioSyent logo

BioSyent(OTC) BIOYF

Market Cap$119.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+1,957%
5 Year+75%
1 Year+30%
1 Month+2%
$10.53
+0.86%
+0.09Today
BioSyent last closing stock price
MetricPriceDate
Last closeUSD 10.442026-07-31
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.38%USD 10.402026-07-24
1 month+2.25%USD 10.212026-07-01
3 month-2.05%USD 10.662026-05-01
Year to date+10.48%USD 9.452025-12-30
1 year+30.39%USD 8.012025-07-31
3 year+94.85%USD 5.362023-08-01
5 year+74.85%USD 5.972021-07-30
Since inception+1,956.97%USD 0.512012-06-01

BioSyent Financials at a Glance

Market Cap

$119.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$46.01M

Net Income (TTM)

CA$9.04M

EPS (TTM)

$0.57

P/E Ratio

18.00

Dividend

$0.15

Beta (Volatility)

0.19 (Low)

Price

$10.53

Volume

175

Open

$10.53

Previous Close

$10.53

Daily Range

$10.53 - $10.53

52-Week Range

$7.63 - $12.00

Estimated Earnings Date

Aug 27, 2026

BIOYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a healthcare company focused on acquiring, developing, and selling pharmaceutical products in Canada and internationally. The company specializes in addressing various medical needs, particularly in the areas of iron deficiency anemia and women's health.

Products and Services
  • FeraMAX Pd Therapeutic 150 for iron deficiency anemia treatment
  • Tibella, a hormone replacement therapy for menopausal symptoms
  • Inofolic, a natural health product for polycystic ovarian syndrome
Growth Outlook
  • Recent quarterly revenue reached CAD 13.9 million, a significant increase
  • Strong demand for iron supplements and women's health products drives growth
  • Expansion into international markets is expected to enhance revenue streams
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 49.5 million reflects robust performance
  • Net income margin of 19.65% indicates strong profitability
  • Current ratio of 1.89 suggests solid liquidity position
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, particularly in niche markets such as iron deficiency and women's health. The company's diverse product portfolio, including FeraMAX and Tibella, addresses critical health issues, positioning it well for future growth. Recent financial performance highlights a strong revenue trajectory, with a notable increase in quarterly revenue, reflecting effective market strategies and product demand. The company's solid liquidity and profitability metrics further enhance its attractiveness to potential investors. As BioSyent continues to explore international opportunities, it is poised for sustained growth in the evolving healthcare landscape.
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

BIOYF Financials

Key Financial Metrics (TTM)

Gross Margin

74.11%

Operating Margin

25.10%

Net Income Margin

19.65%

Return on Equity

22.05%

Return on Capital

26.74%

Return on Assets

14.46%

Earnings Yield

5.56%

Dividend Yield

1.46%

Payout Ratio

25.54%

Stock Overview

Market Cap

$119.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.44M

Volume

175

Avg. Volume

2.89K

Financials (TTM)

Gross Profit

CA$34.10M

Operating Income

CA$11.55M

EBITDA

CA$13.12M

Operating Cash Flow

CA$13.02M

Capital Expenditure

-CA$325.45K

Free Cash Flow

CA$12.69M

Cash & ST Invst.

CA$10.93M

Total Debt

CA$5.26M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 21,450,330-6.0%
20232023-12-31CAD 23,405,6519.1%
20242024-12-31CAD 25,570,7159.3%
20252025-12-31CAD 30,811,08920.5%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.3%
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3144.3%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.33-14.1%
20232023-12-31CAD 0.3917.6%
20242024-12-31CAD 0.4514.3%
20252025-12-31CAD 0.5624.7%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.0%
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$13.94M

+27.0%

Gross Profit

CA$9.70M

+16.4%

Gross Margin

69.59%

N/A

Market Cap

$119.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$167.95K

N/A

Employees

711

N/A

Net Income

CA$2.35M

+1.3%

EBITDA

CA$3.67M

+8.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$10.93M

-37.2%

Total Debt

CA$5.26M

+431.3%

Accounts Receivable

CA$7.57M

+38.2%

Inventory

CA$11.32M

+114.5%

Long Term Debt

CA$815.30K

+3.4%

Short Term Debt

CA$4.43M

+2097.1%

Return on Assets

14.46%

N/A

Return on Invested Capital

25.13%

N/A

Free Cash Flow

CA$2.93M

+463.7%

Operating Cash Flow

CA$2.96M

+512.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVFFCannara Biotech Inc.
$1.42+7.33%
GRUSFGrown Rogue International Inc.
$0.39-8.56%
SPHRYStarpharma Holdings Limited
$4.64-5.07%
PLNHPlanet 13 Holdings Inc.
$0.12-5.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About BIOYF

What is the current price of BioSyent?

BioSyent is trading at $10.53 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between $7.63 and $12.00.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$3.76M.

How much cash does BioSyent have on hand?

BioSyent reported CA$4.40M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.46%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services